Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01272076 · ClinicalTrials.gov registry record

Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)

A clinical trial of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Carl Zeiss Meditec.

Completed
Registry status
85
Enrollment target
2
Study locations

NCT01272076 is a study of Age-related Macular Degeneration and Geographic Atrophy that has completed, run by Carl Zeiss Meditec. The registered enrollment target is 85 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01272076, a study of Age-related Macular Degeneration and Geographic Atrophy, has completed, sponsored by Carl Zeiss Meditec.

COMPLETED
Registry status
85 participants
Enrollment target
2
Study locations

Study Summary

The objective of this study is to compare Cirrus HD-OCT automated measurements of the illumination area under the retinal pigment epithelium (RPE) to expert manual measurements of areas of hypofluorescence typical of geographic atrophy in fundus autofluorescence (FAF) images.

Study Locations (2)

California

  • East Bay Retina Consultants, Inc. - Oakland

Michigan

  • TLC Eyecare and Laser Centers - Jackson

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2011-01
Est. Completion 2011-02

Sponsor

Carl Zeiss Meditec

18 total trials

What the Registry Record Tells You About NCT01272076

The ClinicalTrials.gov registry entry for NCT01272076 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (94% lower). The listed sponsor is Carl Zeiss Meditec, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 0 interventions.

NCT01272076 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Michigan.

Frequently Asked Questions

What is clinical trial NCT01272076 about?

NCT01272076 is a clinical study titled "Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)". The objective of this study is to compare Cirrus HD-OCT automated measurements of the illumination area under the retinal pigment epithelium (RPE) to expert manual measurements of areas of hypofluorescence typical of geographic atrophy in fundus autofluorescence (FAF) images.

What is the current status of trial NCT01272076?

This trial is currently completed. The enrollment target is 85 participants. The study started on 2011-01. Estimated completion is 2011-02.

What conditions does trial NCT01272076 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Geographic Atrophy.

Who is sponsoring clinical trial NCT01272076?

This trial is sponsored by Carl Zeiss Meditec, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01272076 being conducted?

This trial has 2 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.